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Background: Severe hypertension (SHT) (Blood Pressure, BP≥ 180/110 mmHg) is associated with considerable
morbidity and mortality, yet little is known about how it is managed. The purpose of this study is to examine
the management of SHT by Australian general practitioners (GPs) and to explore its variance across patient
characteristics and clinical practices.
Methods: Review of electronic medical records for a year before and after a recorded measure of SHT in 7,499
patients by 436 GPs in 167 clinics throughout Australia during 2008–2009. Outcome measures included follow-up,
referral, changes to antihypertensive drug treatment, and BP control (normotensive reading, BP < 140/90 mmHg,
and whether subsequent recorded measures were also in the normal range - sustained normotension).
Results: Of 7,499 patients with an electronic BP record of SHT, 94% were followed up (median time 14 days); 8%
were referred to an appropriate specialist (median time 89 days – 2% within 7 days) and 86% were managed by
GPs. GPs initiated or changed antihypertensive drugs in 5,398 patients (72% of cohort); of these, 46% remained
hypertensive (4% with SHT) and 7% achieved sustained normotension; 6% had no further electronic BP records.
The remaining 14% had no medication changes; among these, 43% remained hypertensive (5% with SHT) and 3%
achieved sustained normotension; 32% had no further electronic BP records. Some outcome measures displayed a
variance across GP clinics that was mostly unexplained by patient or practice characteristics.
Conclusions: Most patients with SHT had at least one follow-up visit and 72% had initiation of, or changes to,
antihypertensive drug treatment. Although most of the patients experienced some improvement, blood pressure
control was poor. Some clinics showed better performance. Suggestions are made for the development of clinical
standards to facilitate appropriate management of this dangerous condition.
Keywords: Severe hypertension, Electronic general practice records, Chronic disease managementBackground
Hypertension is the most common primary diagnosis in
general practice, affecting approximately 1 in 3 adults [1].
It is also the leading risk factor for premature mortality in
the world, contributing to about 45% of all cardiovascular
deaths [1-3], and is the second highest ranked cause of
disability. There is compelling evidence that systolic
blood pressure (BP) above optimal levels proportionally
increases the risk of stroke, coronary heart disease and
chronic kidney disease. In particular, individuals with* Correspondence: b.gallego@unsw.edu.au
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reproduction in any medium, provided the orsevere hypertension (SHT), defined as systolic BP ≥
180 mmHg or diastolic BP ≥ 110 mmHg, are at serious
short-term risk of cardiovascular events, have 10 year
cardiovascular disease risks of about 20%, and high
rates of target organ complications [4-7].
Although hypertension is easy to diagnose and inexpensive
to treat, a significant gap has been documented between
recommended and received care [8-14]. A report by the
Institute of Medicine in the United States calls hyper-
tension a “neglected disease”, and attributed this to lack
of adherence to treatment guidelines, since 86% of people
with hypertension visit their doctors [15]. Other authors
suggest that primary care physicians may not be aggressive
enough in managing hypertension and are willing tol Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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particularly in the elderly [17,18]. At the other end of
the adult age band, authors of a large Australian study
found that lack of treatment for hypertension was also
associated with perceived low risk in young, non-obese,
non-diabetic males [12].
Because of the dangers associated with SHT, prompt,
adequate management is essential. The need for prompt
follow-up and/or referral to a specialist, and appropriate
combinations of drugs to achieve BP control (BP < 140/
90 mmHg) is emphasized in guidelines [4,19]. Yet previous
studies of SHT management [20-22] have provided evi-
dence that treatment is often inadequate in relation to
the serious risks faced by these patients.
In this paper we examine key aspects of the management
of patients with SHT in Australian general practice. In
particular, we focus on the responses by general prac-
titioners (GPs) to the presence of SHT via follow-up,
referral, and addition of, or changes to, antihypertensive
drug treatment; and report on subsequent recorded BP
measures during one year of follow-up. In addition we
explore how much of the variance in follow-up and BP




The electronic medical records analysed in this study
were collected by the General Practice Research Network
(GPRN) (http://www.hcn.com.au/Products/Strategic+Solutions)
[23], a national network of Australian GPs. To date, more
than 1,000 GPs have contributed to this dataset; in the
study period under consideration there were 436 GPs in
167 clinics distributed across all 8 states and territories
with a mean representation of 38 GPs per 100,000 inhabi-
tants and 68% of these practices in metropolitan areas.
All patients with a BP measurement of SHT (BP ≥ 180/
110 mmHg) between March 1, 2008 and March 1, 2009
were selected. Their records one year before and after
the first recording of this SHT measure (reference visit)
were examined. The 45 patients who died in the follow-up
year were excluded since they represent a very small
percentage of the sample size (<1%) and may have
complications or other adverse events (not controlled
for) other than hypertension. If more than one BP was
recorded or there was more than one visit on a day, the
BP values for that day were averaged.
The patient characteristics included in this study were
sex, age (at reference visit), number of visits and recorded
measures of SHT during the previous year, diabetes
status, and the last available measure of total cholesterol
to high density lipoprotein ratio (CHOL:HDL) up to and
including the reference visit. Only 0.09% of patients had
missing age; cholesterol measures were classified as >4.5,≤4.5 or missing. The characteristics of GPs and practices
included age and years from graduation (at March 2008),
sex, country of graduation, practice size (the number of
GPs in that practice – part-timers were weighted by 0.5)
and practice location (rural or metropolitan). A very small
number of GPs had missing age (1%), year of graduation
(1%) and country of graduation (5%); and 1% of clinics
had missing size.
Outcome measures were: (a) Follow-up visits to the same
practice and time to first follow-up visit from the reference
visit; (b) Addition of, or changes to, anti-hypertensive
drug treatment during the year after the reference visit;
these drugs were classified into angiotensin 1 (AT1)
receptor blockers, angiotensin converting enzyme (ACE)
inhibitors, beta-blockers, calcium channel blockers,
diuretics and others; (c) first normotensive reading
(BP <140/90 mmHg) (normotension), interval before
first normotensive reading and whether all subsequent
recorded measures were also in the normal range (sus-
tained normotension). Outcome measures (b) and (c) were
computed only for patients with at least one follow-up
visit who were not referred to a specialist. Here, specialists
included cardiology, endocrinology, renal medicine and/or
geriatrics. Sustained normotension required a minimum
of 2 BP measures.This study was approved by the UNSW
Human Research Ethics Committee (09154).Statistical analysis
A hierarchical logistic regression model, with a patient and
a GP clinic level, allowed us to investigate if the occurrence
of a follow-up visit clustered by GP clinic and how
much of the variance could be explained by some patient,
GP and GP clinic characteristics. Failure to adhere or
sustain normotension was also modeled using similar
two-level hierarchical models. Practices with less than 20
SHT patients, as well as patients for whom normotension
(or sustained normotension) could not be calculated, were
excluded from the regression analysis. No imputation on
other missing data (which was negligible) was performed.
Multilevel models recognise the existence of data
hierarchies and are a preferred method for examining
variations in outcomes across institutions, providers,
and other relevant groups [24]. The parameters of the
regression models were estimated using SAS PROC
GLIMMIX with random intercepts, residual pseudo-
likelihood estimation and the Cholesky algorithm [25].
We also computed the intraclass correlation coefficient
(ICC), which described how strongly outcomes within
one GP/practice resembled each other, and was estimated
following the linear threshold method by Snijders and
Bosker [26]; and the median value of the odds ratios’
second level (MOR) [27], which measured the extent to
which an outcome was determined by the GP clinic.
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The selection criteria resulted in a sample of 7,499 patients
with at least one recorded measure of SHT (see Figure 1);
these had 78,757 visits to 436 GPs in 167 GP clinics during
the follow-up year (including the reference visit). The
variables characterising these patients, GPs and GP
clinics are summarised in Table 1.
Most of the 7,499 patients (94%) had a follow-up visit
with a median of 14 days (see Figure 2); 66% of these
patients visited more than one doctor within the same
practice. Referral to an appropriate specialist took place
in 8% of patients after a median of 89 days – 2% within
7 days (see Figure 2). The remaining 6,416 patients (86%)
were managed solely by GPs. Older, diabetic patients or
patients with previous SHT episodes were more likely
to be referred to specialists.
Antihypertensive drug treatment and BP control were
analysed for the patients managed by their GPs; 14%
(of the total cohort) had no change or addition to their
antihypertensive drugs, 26% were prescribed one anti-
hypertensive drug, 26% a combination of 2, and 20% a
combination of three or more. Overall, 38% of patientsEligible for study (N=
At least one follow-up vis
Neither new nor changes in 
antihypertensive drugs (N=1,018)
Hypertension (N=436)





Unknown Blood Pressure (N=321)
Patients with a measure
Hypertension (SHT) (N
Figure 1 Summary illustration of the numbers of patients with severe
in antihypertensive drugs treatment and blood pressure (BP) controlhad at least one normotensive reading after a median of
88 days, (see Figure 2). For 633 patients there was no
electronic record of a further blood pressure measurement;
the free narratives (possibly containing BP records) were
not available for study.
Comparisons between patients with and without changes
in antihypertensive medication are summarised in Table 2.
Patients with new or changes in antihypertensive drug
treatment were more likely to have a recorded BP measure
during the study period (94% vs. 68%). They were also
more likely to reach normotension (48% vs. 26%) and less
likely to have further measures of SHT (4% vs. 5%).
Variance in the occurrence of a follow-up visit
Among the 106 clinics with at least 20 SHT patients,
14% provided follow-up visits for all their patients; the
practice with the lowest follow-up had a rate of 73% (see
Figure 3). There was a statistically significant difference
in follow-up rates across GP clinics (pFisher < 0.0001); the
median was 95% and the standard deviation was 6%; a
similar variance was found across GPs.7,499)
No follow-up visit (N=483)
it (N=7,016)
Referred to specialist (N=600)
New or changes in antihypertensive 
drugs (N=5,398) 
Hypertension (N=2,471)





Unknown Blood Pressure (N=312)
 of Severe 
=7,544)
Died (N=45)
hypertension (SHT) with respect to follow-up, referral, changes
during the year of follow-up.
Table 1 Summary statistics
Patients (n=7,499) mean number of visits per patient in the
following year = 11
Sex Male = 41%
Female = 59%
Age Median 68 years (25th percentile
55 years, 75th percentile 78 years)
Visits during previous year Median 2 visits (25th percentile
0 visits, 75th percentile 5 visits)
Severe hypertension measures
during previous year
Median 0 measures (25th percentile 0
measures, 75th percentile 0 measures)
Total cholesterol to HDL ratio Unknown = 73%
≤ 4.5 = 7%
>4.5 = 20%
General practitioners (n=436) mean number of visits per general
practitioner in following year = 181
Sex Male = 65%
Female = 35%
Age Median 48 years (25th percentile
39 years, 75th percentile 56 years)
Years from graduation Median 23 years (25th percentile
15 years, 75th percentile 31 years)
General practice clinics (n=167) mean number of visits per clinic in
following year = 472
Number of general
practitioners in clinic*
Median 2 GPs (25th percentile 1 GP,
75th percentile 4 GPs)
Practice location Metropolitan = 68%
Rural = 32%
*Weighted as 0.5 if doctor works.
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statistically significant association with lack of follow-up
visit (see Table 3). Male, younger, non diabetic patients
with unknown CHOL:HDL, fewer visits and fewer SHT
recorded measures in the previous year were less likelyFigure 2 Times to follow-up, referral, a normotensive reading and su
calculated with respect to the full cohort of 7,499 patients. Shaded areas coto have a follow-up visit. For example, the odds ratio of
having a follow-up visit if cholesterol measures were
known was 3.4 [95% CI = (1.9, 6.1)]. Neither GP nor GP
clinic characteristics had a statistically significant effect.
A hierarchical multivariate logistic regression model
showed clustering by GP clinic after adjusting for
patient characteristics (ICC = 10%, MOR = 1.8). Patient
characteristics explained some of the model variance
(Entropy R2 = 6.6%) while both GP and GP clinic charac-
teristics had no influence.
Variance in the achievement of normotension
The median and standard deviation in the percentage
of patients achieving normotension among the 106 GP
clinics with at least 20 SHT patients were 39% and 14%
respectively (highest percentage of patients achieving
normotension was 75%, lowest rate 0%) (see Figure 3).
There were 11 clinics for which no patient sustained
normotension (see Figure 3), and the difference in
normotension rates across GP clinics was statistically
significant (pFisher < 0.0001).
Clinics with higher rates of follow-up had, on average,
higher rates of achievement of normotension (p < 0.005).
Rates of sustained normotension were low and did not
show an association with follow-up rates.
Male patients and patients with unknown CHOL:HDL
were independently less likely to achieve normotension, but
not less likely to sustain it. The issue of a prescription of
some drugs during the year of follow-up was independently
associated with normotension. Patients prescribed AT-1
receptor blockers, ACE inhibitors and combinations of
anti-hypertensive drugs were more likely to achieve
normotension during the year of follow-up. In particular,
prescription of AT-1 receptor blockers was also associated
with sustaining normotension [odds ratio = 1.8, 95% CI =
(1.1, 2.9)]. GP clinic location and GP country of graduationstained normotension during the study year. Percentages are
rrespond to 50% of patients (median time).
Table 2 Summary statistics of blood pressure (BP) control
Total New or changes in antihypertensive drugs p-value (χ2 test)
No Yes
Sample size 6,416 (100%) 1,018 (100%) 5,398 (100%)
Hypertension 2,907 (45.3%) 436 (42.8%) 2,471 (45.8%) 0.08
Severe (SHT) 254 (4.0%) 51 (5.0%) 203 (3.8%) 0.06
Normotension 2,876 (44.8%) 261 (25.6%) (25.6%) 2,615 (48.4%) <0.0001
Unsustained 1,884 (29.3%) 101 (9.9%) 1,783 (33.0%) <0.0001
Sustained 404 (6.3%) 33 (3.2%) 371 (6.9%) <0.0001
Unknown 588 (9.2%) 127 (12.5%) 461 (8.5%) <0.0001
Unknown BP 633 (9.9%) 321 (31.6%) 312 (5.8%) <0.0001
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achieving (but not sustaining) normotension, with clinics
in metropolitan areas and GPs graduated in Australia
performing slightly better (see Table 3).
When modelling BP control using a hierarchical multi-
variate regression model, none of the available GP and
GP clinic characteristics had an effect. Both achieving and
sustaining normotension were found to cluster by GP
clinic after adjusting for patient characteristics (ICC = 6%,
MOR = 1.5%).
Discussion
This study was designed to explore responses by Australian
GPs to SHT by looking at 4 basic measures: follow-up
visits, initiation of, or changes to, antihypertensive drug
treatment, and BP control. This is the first analysis that
explores the variance in the response of GPs to measures
of SHT.
Follow-up (94%) occurred with a median of 2 weeks,
but only 8% of patients were referred to an appropriate
specialist (at a median of 89 days). The follow-up time isFigure 3 Distribution of the percentage of patients with follow-up vis
sustained normotension by general practice (GP) clinic. Only GP clinics
Percentages are calculated with respect to the full cohort of 7,499 patients
follow-up visits.better than that found in other studies [22], but only 2%
were referred within 1 week, which is lower than the 4%
compliance for this indicator found in the CareTrack
Australia study [14]. Of the 6% of patients who had no
follow-up, 93% had not had a measure of SHT in the
past and were more likely to be perceived as being of
low risk of hypertension-related disease. We also found
that 14% of patients did not receive an initiation of, or
change to, anti-hypertensive drug treatment, even though
63% of those for whom BP measures were available did
not achieve normotension (versus 49% among those
who had a change in medication). This is also consistent
with previous work [22]. Overall, 5% of all patients (6% of
those followed and with available BP measures) achieved
and sustained normotension for the year of follow-up.
Not all visits had an electronic record of blood pressure
measurement. Conservatively assuming that BP in all
the GP visits for which it was not recorded was in the
normal range, no more than 7% of the followed patients
would have achieved normotension and would have
sustained it till the end of the study year.its, who had a normotensive reading, and who achieved and
with 20 or more severe hypertension (SHT) patients are included.
. Clinics were sorted from lowest to highest percentage value of
Table 3 Univariate and multivariate models of follow-up and blood pressure (BP) control
Modelling lack of follow-up visit
(106 clinics; 6,993 patients)*
Modelling hypertension
(82 clinics; 5,057 patients)**
Modelling unsustained normotension







Effect Statistic† (p-value) Point estimate (p-value) Statistic† (p-value) Point estimate (p-value) Statistic† (p-value) Point estimate (p-value)
Patient
Sex (ref=female) male χ2= 7.21 (0.03) 0.11 (0.3) χ2= 33.37 (<0.0001) 0.33 (<0.0001) χ2= 0.78 (0.68) N/A
Age −0.03 (<0.0001) −0.03 (<0.0001) −0.008 (<0.0001) −0.007 (0.0007) 0.01 (0.003) 0.01 (0.02)
Previous visits −0.27 (<0.0001) collinear with prev. SHT −0.07 (<0.0001) collinear with prev. SHT −0.03 (0.01) collinear with prev. SHT
Previous SHT −0.66 (<0.0001) −0.45 (0.0008) −0.09 (<0.0009) 0.17 (<0.0001) −0.21 (0.02) 0.16 (0.07)
Total CHOL/HDL
(ref=unknown)
>4.5 χ2= 69.70 (<0.0001) −1.23 (<0.0001) χ2= 30.16 (<0.0001) −0.05 (0.64) χ2= 0.20 (0.9) N/A
≤4.5 −1.05 (<0.0001) −0.32 (<0.0001) N/A
Diabetic Status
(ref=no)
yes χ2= 23.17 (<0.0001) −1.06 (0.0003) χ2= 0.98 (0.32) N/A χ2= 0.05 (0.83) N/A





χ2=70.01 (<0.0001) −0.64 (<0.0001) χ2= 17.93 (0.02) −0.59 (0.01)




Beta blocker −0.34 (0.14)
Diuretics −0.48 (0.08)








Sex (ref=male) female χ2= 1.23 (0.27) N/A χ2=1.84 (0.17) N/A χ2= 0.36 (0.55) N/A
Age −0.01 (0.08) collinear with years grad. −0.02 (0.6) collinear with years grad. −0.001 (0.85) collinear with years grad.
Years graduation −0.01 (0.05) 0.002 (0.75) −0.06 (0.07) 0.004 (0.33) 0.004 (0.55) N/A
Place graduation





















Table 3 Univariate and multivariate models of follow-up and blood pressure (BP) control (Continued)
Clinic
Size −0.01 (0.45) N/A −0.02 (0.32) N/A −0.02 (0.25) N/A
Location
(ref=Metropolitan) rural χ2= 0.14 (0.71) N/A χ2= 6.20 (0.01) 0.04 (0.72) χ2= 0.05 (0.82) N/A
*Only clinics with 20 or more patients were included in the analyses.
**Only clinics with 20 or more patients and patients with at least 1 BP measure were included in the analyses.
†Chi square test for categorical variables and logistic regression estimate for continuous variables.





















Gallego et al. BMC Health Services Research 2013, 13:414 Page 8 of 9
http://www.biomedcentral.com/1472-6963/13/414The demographics of the GPs and GP clinics had very
little effect on the observed management of SHT, and only
some of the observed variance was explained by patient
characteristics. Nevertheless, it is clear that some clinics
performed better than others (see Figure 3).
Limitations
This study provides a description of GP responses to the
management of SHT and does not attempt to address
the more complex issue of adherence to hypertension
guidelines. All the patients’ information was extracted from
the electronic records of the GPRN dataset. Therefore,
visits by the same patient to other GP clinics or acute care
centres were not accessed. It would have been desirable to
include more information about patient comorbidities,
as well as other patient outcomes such as stroke or
heart attack rates; however this was considered beyond
the scope of this study. There was no electronic record
of a blood pressure measurement for 53% of the follow-up
visits, a proportion of these missing measurements may
have been recorded as free text, which was not available
for this study. In this analysis, blood pressure has been
treated as a categorical variable. Therefore, only changes
in blood pressure across predefined categories were taken
into account.
Implications for policy, practice and further work
Decisions about care during a healthcare encounter are
the result of a complex interplay among the demographics
and co-morbidities of individual patients, the attitudes,
knowledge and beliefs of both doctors and patients,
and other socio-economic and clinical factors [28].
Nevertheless, this study suggests that severely hypertensive
patients are not being managed aggressively enough, that
more intensive treatments lead to better outcomes, and
that it is possible for some practices to do better.
One possible explanation is the failing to escalate care
in the presence of competing demands from multiple
comorbidities [29,30]. For some patients, multidrug
therapy or significant secondary effects from drugs may
limit anti-hypertension treatment. For example, using
AT1 receptor blockers and ACE inhibitors in elderly
patients with renal impairment is not recommended, since
they can worsen renal failure. Promoting and facilitating
adherence to drug treatment (for example using dose
administration aids) can improve BP control [31].
Also, the high prevalence of blood pressure above the
normal range may make practitioners and patients more
accepting of ongoing recording of high blood pressure.
Poor understanding of the risks of SHT among some
patients (such as younger males with unknown lipid
measures and infrequent visits) could also be behind
inappropriate follow-up and poor achievement of BP
control. Absence of lipid measures might also reflect GPpractices likely to be associated with failure to adequately
follow up on hypertensive patients.
Adherence to simple processes of escalating care as
necessary, in line with existing guidelines, would result
in safer, more effective treatment [32]. Improved, more
relevant and user-friendly tools for management of
chronic conditions at the point of care are also needed.
Recommendations have recently been made for national
agreement on clinical standards for the basic care of
common conditions, for developing tools to guide and
document management, and for providing feedback to
patients and practitioners. Developing and implementing
these with respect to hypertension must be high on the
national agenda, as it is clear that more needs to be done
to improve the management of this dangerous condition.
Conclusions
This study provides evidence of responses by Australian
GP’s to measures of SHT using electronic health records.
A large proportion of patients (94%) had at least one
follow-up visit and initiation of, or changes to, antihy-
pertensive drug treatment took place in 72% of patients.
Nevertheless, blood pressure control in these patients
was poor. It appears that more aggressive management
of severe hypertension is needed and that it is possible
for some practices to do better.
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